Licensing Onsite Synthesis Molecular Assemblies launched a Partnering Program to license its Fully Enzymatic Synthesis technology for onsite DNA synthesis, offering industrial synthetic biology, precision medicine, nanotech, and biobased electronics players a path to pilot and deploy FES within their facilities.

Acquisition Channel Recent asset sale and IP transfer to Maravai creates a potential channel to pursue licensing or collaboration with the new owner, offering opportunities to monetize FES through strategic partnerships or integration with Maravai product lines.

Sustainability Value FES promises long high quality DNA synthesis with lower cost and a more sustainable footprint compared to traditional methods, enabling customers in biotech manufacturing to differentiate through greener and scalable DNA production.

Market Credibility Past financing from notable investors including Agilent and industry award recognition signal credible technology and market validation, making Molecular Assemblies a compelling partner for large biotechs or contract manufacturers seeking differentiated DNA synthesis capabilities.

Lean Deployment Model With a small team and a licensing focused business model, MAI can scale through partner led deployment and co development deals, targeting mid to large cap customers that can absorb licensing for onsite synthesis without heavy internal infrastructure.